According to the analysts, the company's Q2 results demonstrated sequential stabilization of the company's core vascular intervention businesses for peripheral and coronary intervention, clearing the way for the company's Stellarex drug-coated balloon (DCB) platform to take over as the central value driver for the stock.
"By our analysis, >50 percent of our projected 12-month target valuation is now driven by the long-term growth and value associated with Stellarex," UBS said.
At time of writing, Spectranetics was up 4.28 percent on the day at $24.08.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.